Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simufilam in mild-to-moderate Alzheimer's disease
NCT05026177Phase 3Terminated
- Sponsor
- Cassava Sciences
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of simufilam in Alzheimer's disease (AD) (3 arms), sponsored by Cassava Sciences. Primary endpoints: Alzheimer's Disease Assessment Scale - Cognitive Subscale (12-item) at 76 weeks and Alzheimer's Disease Cooperative Study - Activities of Daily Living at 76 weeks. Started Nov 2021; status: terminated.
02
Drugs
simufilam
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05026177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05026177.